

HR 3348

Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Jul 20, 2017

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Jul 20, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/3348>

Sponsor

Name: Rep. Peters, Scott H. [D-CA-52]

Party: Democratic • **State:** CA • **Chamber:** House

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Boyle, Brendan F. [D-PA-13]	D · PA		Jul 20, 2017
Rep. Marshall, Roger [R-KS-1]	R · KS		Jul 20, 2017
Rep. Rothfus, Keith J. [R-PA-12]	R · PA		Jul 20, 2017
Rep. Delaney, John K. [D-MD-6]	D · MD		Jun 5, 2018
Rep. Fortenberry, Jeff [R-NE-1]	R · NE		Jul 18, 2018

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Jul 20, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Jul 20, 2017)

Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act

This bill amends the Federal Food, Drug, and Cosmetic Act to include Middle East respiratory syndrome under the priority review voucher program for tropical diseases, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)

Actions Timeline

- **Jul 20, 2017:** Introduced in House
- **Jul 20, 2017:** Referred to the House Committee on Energy and Commerce.